CD274 and non-small cell lung carcinoma: This combinatorial strategy has proven to be successful in the landmark PACIFIC trial, where there was a significant OS benefit of adjuvant durvalumab (anti-PD-L1 antibody) after definitive chemoradiation in stage III NSCLC (26).